Making sense of Canada’s specialty pharmaceutical market

Making sense of Canada’s specialty pharmaceutical market

20Sense is a research and consulting firm that works with Canada’s specialty pharmaceutical stakeholders to optimize data, insights and programs that deliver better outcomes for patients and value for payers. 

Outcomes-Based Agreements

20Sense collaborates with forward-thinking pharmaceutical stakeholders to define best practices for building and implementing effective outcome-based innovative market access agreements that support timely and equitable patient access to novel therapies.

Learn more about outcomes-based agreements SVG file icon

Patient Support Programs

20Sense collaborates with Canadian stakeholders to advance PSP capabilities, best practices and standards to best support positive outcomes and access for patients, with a focus on continuous process improvement and real-world data from PSPs.

Learn more about PSPs SVG file icon

decorative

The 20Sense Report

The specialty pharmaceutical industry in Canada is evolving at a rapid pace. Each quarter, The 20Sense Report explores these changes by investigating the topics and initiatives affecting all stakeholders.

Read The 20Sense Report SVG file icon

Our Team

Specialized therapies require a different way of thinking. 20Sense identifies opportunities for Canadian specialty pharmaceutical stakeholders to provide best-in-class solutions for patients.

portrait of Allison and Arif

Recent Publications

20Sense Report Issue 30: Integrating the Patient Voice into Healthcare Decisions

Webinar and panel discussion: The progress and possibilities of innovative payment models in Canada

Poster: Canadian Patient Support Program Enrolment Form Standardization